BALYASNY ASSET MANAGEMENT L.P. - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 145 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.94 and the average weighting 0.0%.

Quarter-by-quarter ownership
BALYASNY ASSET MANAGEMENT L.P. ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$13,031,766
+189.4%
702,900
+93.1%
0.03%
+125.0%
Q4 2022$4,503,521
+1063.7%
364,068
+1212.6%
0.01%
+1100.0%
Q3 2022$387,000
+170.6%
27,736
+167.2%
0.00%
Q2 2022$143,000
-54.6%
10,380
-46.3%
0.00%
-100.0%
Q4 2021$315,000
-91.2%
19,333
-92.0%
0.00%
-93.3%
Q3 2021$3,575,000
+945.3%
240,731
+4326.0%
0.02%
+275.0%
Q1 2020$342,000
-95.4%
5,439
-91.0%
0.00%
-91.1%
Q4 2019$7,509,000
-51.0%
60,595
-52.3%
0.04%
-35.7%
Q3 2018$15,313,000
+106.1%
127,000
+43.4%
0.07%
+112.1%
Q2 2018$7,429,000
+150.7%
88,534
+74.6%
0.03%
+266.7%
Q4 2017$2,963,000
-63.9%
50,716
-64.1%
0.01%
-71.9%
Q3 2017$8,207,000
-40.4%
141,400
+24.4%
0.03%
-43.9%
Q2 2017$13,766,000
+497.0%
113,704
+435.7%
0.06%
+375.0%
Q4 2016$2,306,000
-1.4%
21,227
+49.5%
0.01%
-14.3%
Q3 2016$2,338,00014,2020.01%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2023
NameSharesValueWeighting ↓
Sarissa Capital Management LP 635,300$53,308,00010.69%
Senvest Management, LLC 976,127$81,907,0005.65%
Melqart Asset Management (UK) Ltd 390,600$32,775,0002.80%
Asymmetry Capital Management, L.P. 25,918$2,175,0002.14%
Elk Creek Partners, LLC 386,397$32,423,0001.78%
BB BIOTECH AG 545,719$45,791,0001.32%
ALTRINSIC GLOBAL ADVISORS LLC 383,166$32,151,0001.27%
DLD Asset Management, LP 129,000$10,824,0000.82%
Opus Point Partners Management, LLC 3,998$335,0000.73%
Virtus ETF Advisers LLC 8,970$753,0000.67%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders